US 11,969,499 B2
Hydrogel delivery of sting immunotherapy for treatment cancer
Simon Young, Houston, TX (US); David Leach, Houston, TX (US); and Jeffrey D. Hartgerink, Pearland, TX (US)
Assigned to William Marsh Rice University, Houston, TX (US); and The Board of Regents of The University of Texas System, Austin, TX (US)
Appl. No. 16/618,043
Filed by WILLIAM MARSH RICE UNIVERSITY, Houston, TX (US); and THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Jun. 15, 2018, PCT No. PCT/US2018/037716
§ 371(c)(1), (2) Date Nov. 27, 2019,
PCT Pub. No. WO2018/232217, PCT Pub. Date Dec. 20, 2018.
Claims priority of provisional application 62/520,834, filed on Jun. 16, 2017.
Prior Publication US 2020/0146975 A1, May 14, 2020
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/7084 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 45/06 (2006.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01); A61K 47/69 (2017.01)
CPC A61K 9/0024 (2013.01) [A61K 9/06 (2013.01); A61K 31/7084 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 47/42 (2013.01); A61K 47/64 (2017.08); A61K 47/6903 (2017.08); A61K 2039/55561 (2013.01); A61K 2039/6093 (2013.01); A61K 2039/80 (2018.08); A61K 45/06 (2013.01)] 11 Claims
 
1. A composition comprising (a) a multi-domain peptide (MDP) hydrogel K2(SL)6K2 (SEQ ID NO: 3) or R2(SL)6R2 (SEQ ID NO: 4) and (b) a cyclic dinucleotide (CDN).